| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -65,727 | -44,316 |
| Depreciation and amortization | 4,681 | 3,063 |
| Stock-based compensation expense | 36,761 | 22,271 |
| Change in fair value of derivative liability | 0 | 0 |
| Non-cash lease adjustment | 381 | 254 |
| Inventory write-down | 566 | 490 |
| Provision for credit losses | 1,426 | 900 |
| (gain) loss on foreign currency transactions | 121 | 348 |
| Accounts receivable, net | 3,128 | -1,223 |
| Inventory | 10,500 | 11,068 |
| Prepaid expenses and other current assets | 671 | -1,089 |
| Other assets | 1,973 | 1,165 |
| Accounts payable | 715 | 1,504 |
| Accrued compensation | 207 | -5,248 |
| Accrued interest expense | 94 | 52 |
| Loan facility liability | -2,000 | - |
| Deferred revenue | 1,352 | 223 |
| Reimbursements for leasehold improvements from operating leases | 0 | 0 |
| Loan facility liability | - | -2,000 |
| Other liabilities | 41 | 1,561 |
| Net cash used in operating activities | -38,658 | -32,023 |
| Purchases of property and equipment | 7,506 | 4,638 |
| Net cash used in investing activities | -7,506 | -4,638 |
| Proceeds from issuance of common stock from the exercise of stock options | 3,249 | 2,171 |
| Proceeds from issuance of common stock under employee stock purchase plan | 3,504 | 3,505 |
| Net cash provided by financing activities | 6,753 | 5,676 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | -33 | -23 |
| Net decrease in cash, cash equivalents and restricted cash | -39,444 | -31,008 |
| Cash and cash equivalents at beginning of period | 336,763 | - |
| Cash and cash equivalents at end of period | 297,319 | - |
PROCEPT BioRobotics Corp (PRCT)
PROCEPT BioRobotics Corp (PRCT)